Novofem Filmuhúðuð tafla 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

novofem filmuhúðuð tafla

novo nordisk a/s* - estradiol; norethisteronum acetat - filmuhúðuð tafla

Trisekvens Filmuhúðuð tafla 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

trisekvens filmuhúðuð tafla

novo nordisk a/s* - estradiol; norethisteronum acetat - filmuhúðuð tafla

Activelle Filmuhúðuð tafla 1mg/0,5 mg 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

activelle filmuhúðuð tafla 1mg/0,5 mg

novo nordisk a/s* - norethisteronum acetat; estradiolum inn - filmuhúðuð tafla - 1mg/0,5 mg

Ovestin Leggangakrem 1 mg/g 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

ovestin leggangakrem 1 mg/g

aspen pharma trading limited - estriolum inn - leggangakrem - 1 mg/g

Ovestin Leggangastíll 0,5 mg 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

ovestin leggangastíll 0,5 mg

aspen pharma trading limited - estriolum inn - leggangastíll - 0,5 mg

Estring Leggangainnlegg 7,5 míkróg/24 klst. 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

estring leggangainnlegg 7,5 míkróg/24 klst.

pfizer aps - estradiol - leggangainnlegg - 7,5 míkróg/24 klst.

Femanor Tafla 2 mg+1 mg 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

femanor tafla 2 mg+1 mg

viatris aps - norethisteronum acetat; estradiol - tafla - 2 mg+1 mg

Cyproteroneacetat/etinylestradiol Alvogen (Cypretyl) Húðuð tafla 2/0,035 mg 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

cyproteroneacetat/etinylestradiol alvogen (cypretyl) húðuð tafla 2/0,035 mg

alvogen ehf. - ethinylestradiolum inn; cyproteronum acetat - húðuð tafla - 2/0,035 mg

Mirena (Levonova) Leginnlegg 20 míkróg/24 klst. 아이슬란드 - 아이슬란드어 - LYFJASTOFNUN (Icelandic Medicines Agency)

mirena (levonova) leginnlegg 20 míkróg/24 klst.

bayer ab* - levonorgestrelum inn - leginnlegg - 20 míkróg/24 klst.

Orserdu 유럽 연합 - 아이슬란드어 - EMA (European Medicines Agency)

orserdu

stemline therapeutics b.v. - elacestrant - brjóstakrabbamein - innkirtla meðferð - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.